The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out

384: 2092-101. 2 Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384: 2202-11. 3 MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States, April 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 651-56. 4 Borobia AM, Carcas AJ, Perez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 2021; 398: 121-30. 5 Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; published online May 17. https://doi.org/10.1038/s41591-02101377-8.

Automated summary

The information above covers topics such as clotting issues after COVID-19 vaccination, comparing immunogenicity between different vaccines, and the relationship between neutralizing antibodies and protection from SARS-CoV-2 infection.